ProKidney Corp (PROK) concluded trading on Wednesday at a closing price of $3.22, with 5.56 million shares of worth about $17.91 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 79.89% during that period and on July 23, 2025 the price saw a gain of about 5.57%. Currently the company’s common shares owned by public are about 129.54M shares, out of which, 97.12M shares are available for trading.
Stock saw a price change of -13.67% in past 5 days and over the past one month there was a price change of 431.35%. Year-to-date (YTD), PROK shares are showing a performance of 52.61% which increased to 90.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.46 but also hit the highest price of $7.13 during that period. The average intraday trading volume for ProKidney Corp shares is 12.79 million. The stock is currently trading 29.10% above its 20-day simple moving average (SMA20), while that difference is up 118.14% for SMA50 and it goes to 121.57% higher than SMA200.
ProKidney Corp (NASDAQ: PROK) currently have 129.54M outstanding shares and institutions hold larger chunk of about 40.75% of that.
The stock has a current market capitalization of $942.52M and its 3Y-monthly beta is at 1.68. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 10.96. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PROK, volatility over the week remained 13.89% while standing at 40.40% over the month.
Stock’s fiscal year EPS is expected to rise by 10.31% while it is estimated to decrease by -9.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on June 30, 2025 offering an Underperform rating for the stock and assigned a target price of $1 to it. On September 10, 2024, Guggenheim Initiated their recommendations, while on March 07, 2024, Morgan Stanley Resumed their ratings for the stock with a price target of $3. Stock get a Neutral rating from BofA Securities on January 02, 2024.
